Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.62 |
| ▸ | POLB | P06746 | 2/20 | 0.46 |
| ▸ | CASP6 | P55212 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | GLA | P06280 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | PDK2 | Q15119 | 2/20 | 0.38 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.38 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | PARP1 | P09874 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.36 |
| ▸ | TGM2 | P21980 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24281065 | 0.91 | KMT2A (0.57) | KMT2APOLBCASP6MEN1SMN1; SMN2 | |
| SCHEMBL24281053 | 0.89 | KMT2A (0.70) | KMT2APOLBCASP6MEN1SMN1; SMN2 | |
| SCHEMBL24281322 | 0.84 | KMT2A (0.50) | KMT2APOLBCASP6MEN1SMN1; SMN2 | |
| SCHEMBL24281077 | 0.82 | KMT2A (0.56) | KMT2APOLBCASP6MEN1SMN1; SMN2 | |
| SCHEMBL24281124 | 0.82 | POLB (0.56) | KMT2APOLBCASP6MEN1SMN1; SMN2 | |
| SCHEMBL24281276 | 0.80 | KMT2A (0.76) | KMT2APOLBCASP6MEN1SMN1; SMN2 | |
| SCHEMBL24280992 | 0.78 | KMT2A (0.67) | KMT2APOLBCASP6MEN1HTT | |
| SCHEMBL31317617 | 0.77 | KMT2A (1.00) | KMT2APOLBCASP6MEN1HTT | |
| SCHEMBL24281126 | 0.76 | POLB (0.44) | KMT2APOLBCASP6MEN1ALDH1A1 | |
| SCHEMBL24280971 | 0.76 | KMT2A (0.60) | KMT2APOLBCASP6MEN1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240018103-A1 | 3-HYDROXYOXINDOLE DERIVATIVES AS CRHR2 ANTAGONIST | RAQUALIA PHARMA INC. (JP) | 2024-01-18 | — | — | US | disclosed |
| US-20240018103-A1 | 3-HYDROXYOXINDOLE DERIVATIVES AS CRHR2 ANTAGONIST | RAQUALIA PHARMA INC. (JP) | 2024-01-18 | — | — | US | disclosed |
| WO-2022071484-A1 | 3-HYDROXYOXINDOLE DERIVATIVES AS CRHR2 ANTAGONIST | RAQUALIA PHARMA INC. (JP) | 2022-04-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240018103-A1 | 3-HYDROXYOXINDOLE DERIVATIVES AS CRHR2 ANTAGONIST | CRHR2, CRHR1, CRH | KMT2A 4117/4885POLB 4633/4885CASP6 4455/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.